secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-12-29T23:59:59+00:00
Accession:  0001104659-23-130482
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals shareholders approve share increase, elect director at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Janet Rehnquist as Class II director: 43.7M votes for, 0.5M withheld.
- Approved amendment to 2021 Omnibus Plan: share pool raised from 6,713,608 to 8,713,608 shares; 29.7M for, 13.5M against.
- Ratified Salberg & Company as independent auditor for FY2023: 42.1M for, 1.9M against.
- Advisory 'say-on-pay' approved (32.0M for, 11.4M against); board set future advisory votes on exec compensation to annual.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/tm2333890d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-130482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer